Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

NUVB

Nuvation Bio Inc

Dec 12 • 04:00PM ET

8.43

+0.16 1.93 %

Healthcare • Biotechnology • USA • NYSE

Peers: GILD AMGN REGN VRTX BIIB MRNA BMY PFE LLY SNY

| Held by: IWM VTI IWN IBB VXF SCHA XPH VTWO IHE IWC

Index	RUT	P/E	-	EPS (ttm)	-0.64	Insider Own	30.43%	Shs Outstand	341.76M	Perf Week	-1.40%
Market Cap	2.90B	Forward P/E	-	EPS next Y	-0.50	Insider Trans	-0.26%	Shs Float	239.39M	Perf Month	70.99%
Enterprise Value	2.56B	PEG	-	EPS next Q	-0.10	Inst Own	53.83%	Short Float	21.97%	Perf Quarter	167.62%
Income	-217.48M	P/S	108.36	EPS this Y	71.52%	Inst Trans	-1.99%	Short Ratio	6.08	Perf Half Y	387.28%
Sales	26.75M	P/B	8.87	EPS next Y	16.31%	ROA	-37.08%	Short Interest	52.61M	Perf YTD	216.92%
Book/sh	0.95	P/C	5.28	EPS next 5Y	55.84%	ROE	-52.49%	52W High	8.95 -5.83%	Perf Year	211.07%
Cash/sh	1.60	P/FCF	-	EPS past 3/5Y	-68.86% -49.14%	ROIC	-41.78%	52W Low	1.54 447.40%	Perf 3Y	323.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	48.95%	Volatility	6.60% 9.35%	Perf 5Y	-17.51%
Dividend TTM	-	EV/Sales	95.61	EPS Y/Y TTM	70.51%	Oper. Margin	-870.98%	ATR (14)	0.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.39	Sales Y/Y TTM	1137.19%	Profit Margin	-813.07%	RSI (14)	68.24	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.48	EPS Q/Q	-8.23%	SMA20	13.53%	Beta	1.56	Target Price	11.33
Payout	-	Debt/Eq	0.64	Sales Q/Q	1704.68%	SMA50	50.46%	Rel Volume	0.70	Prev Close	8.27
Employees	220	LT Debt/Eq	0.60	Earnings	Nov 03 AMC	SMA200	165.78%	Avg Volume	8.65M	Price	8.43
IPO	Aug 26, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.16% 98.51%	Trades		Volume	6,074,488	Change	1.93%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Nov-19-25	Initiated	B. Riley Securities	Buy	$12
Sep-30-25	Initiated	Jefferies	Buy	$10
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform	$6
Mar-27-24	Upgrade	Jefferies	Hold → Buy	$1.40 → $10
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy	$5
Jan-06-23	Downgrade	Jefferies	Buy → Hold	$5 → $2
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$8 → $2.50
May-04-22	Initiated	H.C. Wainwright	Buy	$14
Oct-15-21	Resumed	BTIG Research	Buy	$16
Apr-06-21	Initiated	RBC Capital Mkts	Outperform	$15
Mar-08-21	Initiated	Wedbush	Outperform	$20
Mar-08-21	Initiated	Jefferies	Buy	$20
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	BTIG Research	Buy	$16
Mar-08-21	Initiated	BMO Capital Markets	Outperform	$16

Show Previous Ratings

Dec-06-25 10:40PM	Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List (PR Newswire)
Dec-04-25 12:55PM	Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result (Insider Monkey)
Dec-03-25 08:00AM	Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology (Business Wire) +12.05%
Nov-26-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-20-25 06:27AM	Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage (Insider Monkey)
06:17AM	Loading…
Nov-18-25 06:17AM	Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress (Insider Monkey)
Nov-07-25 09:34PM	Is Nuvation Bio (NUVB) One of the Best American Penny Stocks to Buy? (Insider Monkey) -5.78%
Nov-04-25 12:01AM	Nuvation Bio Inc (NUVB) Q3 2025 Earnings Call Highlights: Strong IBTROZI Launch and Robust ... (GuruFocus.com) -6.58%
Nov-03-25 05:55PM	Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Oct-31-25 09:22AM	Nuvation Bio Inc (NUVB) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 05:25PM	MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma (Business Wire) +5.78%
Oct-20-25 04:05PM	Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 (Business Wire) +8.50% +13.78%
01:02PM	Loading…
Oct-08-25 01:02PM	Nuvation Bio Inc. (NUVB): A Bull Case Theory (Insider Monkey)
08:55AM	NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street (PR Newswire)
Sep-30-25 11:33AM	Why Nuvation Bio Stock Is Skyrocketing Today (Motley Fool) +14.91%
07:30AM	Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer (Business Wire)
Sep-19-25 07:30AM	Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Sep-07-25 06:00AM	Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer (Business Wire)
Aug-27-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
09:55AM	Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-25-25 11:56PM	H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB) (Insider Monkey)
Aug-07-25 08:45AM	Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (Business Wire)
Aug-01-25 06:46AM	Nuvation Bio (NUVB)'s Taletrectinib Selected as Preferred Agent for Cancer Treatment (Insider Monkey) -5.51%
Jul-24-25 04:05PM	Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (Business Wire)
09:20AM	Loading…
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 12:00PM	All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy (Zacks) +15.61%
Jun-29-25 03:00AM	Two Beaten-Down Biotech Stocks See Big Insider Buys (Barrons.com)
Jun-24-25 05:33PM	RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating (Insider Monkey) -8.29%
07:00AM	Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers (Business Wire)
Jun-20-25 02:25PM	Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now? (Barchart) +10.06%
Jun-11-25 01:20PM	U.S. Food and Drug Administration Approves Nuvation Bios IBTROZI (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer (Business Wire) -13.04%
12:52AM	FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche (BioPharma Dive)
May-21-25 04:05PM	Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting (Business Wire) -6.45% +10.84%
May-13-25 04:05PM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 (Business Wire)
May-12-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 01:00PM	Nuvation Bio Inc (NUVB) Q1 2025 Earnings Call Highlights: Promising Developments and Strategic Moves (GuruFocus.com)
04:31AM	Nuvation Bio Inc. (NUVB): Among Billionaire David Abrams' Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 06:35PM	Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
09:07AM	Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes (Seeking Alpha)
May-01-25 04:05PM	Nuvation Bio to Present at The Citizens Life Sciences Conference (Business Wire) +8.37%
Apr-22-25 04:05PM	Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 (Business Wire)
Apr-16-25 10:03AM	Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.93%
Apr-13-25 05:40PM	Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-09-25 09:43AM	Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple (Insider Monkey) +7.83%
Apr-02-25 08:00AM	Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference (Business Wire)
Mar-25-25 04:45PM	Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 (Business Wire)
08:00AM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 (Business Wire)
Mar-17-25 03:47PM	Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts? (Insider Monkey)
Mar-09-25 04:11AM	Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts (Insider Monkey)
Mar-06-25 04:30PM	Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Business Wire) +6.88%
Mar-04-25 05:11AM	Nuvation Bio secures $250m for taletrectinib commercialisation (Pharmaceutical Technology)
Mar-03-25 08:35AM	Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners (Business Wire) -7.61%
Feb-24-25 08:00AM	Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire) -5.88%
Feb-03-25 08:00AM	Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Jan-06-25 04:05PM	Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +14.44%
08:00AM	Nuvation Bio Receives Approval from Chinas National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Dec-30-24 03:00PM	Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? (Insider Monkey) -5.07%
Dec-23-24 08:00AM	U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bios New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Dec-20-24 07:10AM	Innovent Receives Approval of DOVBLERON (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration (PR Newswire)
Nov-26-24 08:00AM	Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-24 04:05PM	Nuvation Bio to Present at the Jefferies London Healthcare Conference (Business Wire)
Nov-06-24 04:05PM	Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) +9.48%
01:11AM	Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline (Insider Monkey)
Oct-16-24 09:06AM	Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey) +10.30%
Oct-14-24 11:51AM	Is Nuvation Bio Inc. (NUVB) Hedge Funds Favorite Penny Stock? (Insider Monkey)
Oct-09-24 08:02AM	Growing Confidence in Nuvation Bio, Inc. (NUVB) as Hedge Fund Holdings Increase to 35 (Insider Monkey)
Oct-07-24 04:05PM	Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer (Business Wire) -9.96%
Oct-02-24 02:02AM	Navigating Legal Uncertainty: Nuvation Bio Inc.s Chinese Operations and the Shifting Landscape of Chinas Civil Law System (TipRanks)
Sep-14-24 03:05AM	Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 (Business Wire)
Sep-09-24 08:00AM	Nuvation Bio to Present at the Cantor Global Healthcare Conference (Business Wire) +6.45%
Aug-06-24 06:32AM	Nuvation Bio pauses oncology drug after Phase I efficacy and safety analysis (Clinical Trials Arena) -6.29%
Aug-05-24 02:27PM	Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data (Benzinga) -5.36%
08:00AM	Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-23-24 04:05PM	Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib (Business Wire) +10.06%
Jun-02-24 01:13AM	Innovent Announces TaletrectinibROS1 InhibitorUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting (PR Newswire)
Jun-01-24 08:10AM	Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting (Business Wire)
May-29-24 04:05PM	Nuvation Bio to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 10:54PM	NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024 (InvestorPlace)
05:08PM	Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours (MT Newswires)
04:05PM	Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Apr-24-24 10:01AM	Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Apr-10-24 04:01PM	Nuvation Bio Completes Acquisition of AnHeart Therapeutics (Business Wire) -5.57%
Mar-28-24 08:00AM	Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer (Business Wire) -8.31%
Mar-25-24 07:00AM	Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (Business Wire)
Mar-14-24 04:05PM	Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors (Business Wire) -9.13%
08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-08-24 12:00PM	Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know (Zacks)
Feb-29-24 04:01PM	Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (Business Wire) -5.08% +19.25%
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-08-24 04:10PM	Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors (Business Wire)
04:05PM	Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors (Business Wire)
Nov-13-23 04:05PM	Nuvation Bio Announces Departure of Chief Financial Officer (Business Wire) +5.47%
Nov-02-23 06:04PM	Nuvation Bio Inc (NUVB) Reports Q3 2023 Financial Results (GuruFocus.com) +10.34% +5.47%

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	2.93	150,000	439,500	168,000	Dec 03 05:02 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Sale	7.82	150,000	1,173,255	18,000	Dec 03 05:02 PM
DONGFANG LIU	Officer	Dec 01 '25	Proposed Sale	7.82	150,000	1,173,255		Dec 01 04:51 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 25 '25	Option Exercise	3.61	10,000	36,100	28,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 26 '25	Option Exercise	3.61	10,000	36,100	28,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 26 '25	Sale	8.00	10,000	80,000	18,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 25 '25	Sale	7.50	10,000	75,000	18,000	Nov 26 05:55 PM
DONGFANG LIU	Officer	Nov 26 '25	Proposed Sale	8.00	10,000	80,000		Nov 26 04:33 PM
DONGFANG LIU	Officer	Nov 25 '25	Proposed Sale	7.50	10,000	75,000		Nov 25 04:23 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Nov 20 '25	Option Exercise	1.90	369,051	702,149	300,000	Nov 24 04:09 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Nov 20 '25	Sale	7.23	369,051	2,667,132	0	Nov 24 04:09 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 20 '25	Option Exercise	1.87	20,000	37,400	38,000	Nov 24 04:08 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 20 '25	Sale	7.00	20,000	140,074	18,000	Nov 24 04:08 PM
Hanley David C.	CHIEF TECHNICAL OPERATIONS	Nov 19 '25	Option Exercise	1.87	200,000	374,000	224,000	Nov 21 04:05 PM
Hanley David C.	CHIEF TECHNICAL OPERATIONS	Nov 19 '25	Sale	7.14	200,000	1,427,680	24,000	Nov 21 04:05 PM
GARY HATTERSLEY	Officer	Nov 20 '25	Proposed Sale	7.23	369,051	2,667,132		Nov 20 04:12 PM
DONGFANG LIU	Officer	Nov 20 '25	Proposed Sale	7.00	20,000	140,074		Nov 20 04:07 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Sale	5.10	15,000	76,552	18,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	4.76	15,000	71,475	15,000	Nov 19 04:47 PM
DONGFANG LIU	Officer	Nov 19 '25	Proposed Sale	5.10	15,000	76,552		Nov 19 04:18 PM
DAVID HANLEY	Officer	Nov 19 '25	Proposed Sale	7.14	200,000	1,427,680		Nov 19 04:09 PM
DONGFANG LIU	Officer	Nov 17 '25	Proposed Sale	4.76	15,000	71,475		Nov 17 04:12 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Oct 27 '25	Option Exercise	1.74	100,000	174,000	100,000	Oct 29 04:24 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Oct 27 '25	Sale	5.02	100,000	502,460	0	Oct 29 04:24 PM
GARY HATTERSLEY	Officer	Oct 27 '25	Proposed Sale	4.85	100,000	485,000		Oct 27 04:26 PM
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 18 '25	Buy	1.71	10,000	17,100	29,591	Jun 18 04:05 PM
Sauvage Philippe	Chief Financial Officer	Jun 17 '25	Buy	1.79	4,000	7,160	9,902	Jun 18 04:05 PM
Sauvage Philippe	Chief Financial Officer	Jun 16 '25	Buy	1.83	3,300	6,056	5,902	Jun 18 04:05 PM
Sjogren Colleen	Chief Commercial Officer	Jun 16 '25	Buy	1.81	50,000	90,350	81,000	Jun 18 04:05 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 16 '25	Buy	1.79	50,000	89,740	50,000	Jun 18 04:05 PM
Hung David	PRESIDENT AND CEO	Jun 16 '25	Buy	1.79	500,000	893,500	59,281,054	Jun 18 04:05 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	May 02 '25	Option Exercise	1.94	20,000	38,800	32,000	May 06 04:05 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	May 02 '25	Sale	2.50	20,000	50,024	12,000	May 06 04:05 PM
DONGFANG LIU	Officer	May 02 '25	Proposed Sale	2.27	20,000	45,400		May 02 04:23 PM
Hung David	PRESIDENT AND CEO	Apr 07 '25	Buy	1.62	300,000	487,500	58,781,054	Apr 08 09:30 PM
Hung David	PRESIDENT AND CEO	Apr 04 '25	Buy	1.66	200,000	332,720	58,481,054	Apr 08 09:30 PM
Mashal Robert	Director	Apr 01 '25	Buy	1.67	100,000	166,985	200,000	Apr 03 04:05 PM

Open in Screener

NVCR

NovoCure Ltd

Dec 12 • 04:00PM ET

13.32

-0.34 -2.49 %

Healthcare • Medical Devices • United Kingdom • NASD

Peers: MDT BSX EW ISRG ZBH SYK TFX ALGN PEN RMD

| Held by: VTI IWM VB VBK VXF IWO AVUV IBB SCHA IHI

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	10.33%	Shs Outstand	111.98M	Perf Week	9.99%
Market Cap	1.49B	Forward P/E	-	EPS next Y	-1.49	Insider Trans	0.89%	Shs Float	100.42M	Perf Month	17.25%
Enterprise Value	1.25B	PEG	-	EPS next Q	-0.40	Inst Own	82.92%	Short Float	6.80%	Perf Quarter	4.72%
Income	-177.65M	P/S	2.32	EPS this Y	10.10%	Inst Trans	-5.30%	Short Ratio	3.98	Perf Half Y	-24.10%
Sales	642.27M	P/B	4.37	EPS next Y	-6.51%	ROA	-13.75%	Short Interest	6.83M	Perf YTD	-55.30%
Book/sh	3.05	P/C	1.44	EPS next 5Y	13.08%	ROE	-50.60%	52W High	34.13 -60.97%	Perf Year	-55.18%
Cash/sh	9.25	P/FCF	-	EPS past 3/5Y	-40.48% -83.87%	ROIC	-30.70%	52W Low	10.70 24.49%	Perf 3Y	-82.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.19% 11.49%	Gross Margin	75.52%	Volatility	4.96% 5.03%	Perf 5Y	-91.26%
Dividend TTM	-	EV/Sales	1.95	EPS Y/Y TTM	-15.64%	Oper. Margin	-27.37%	ATR (14)	0.62	Perf 10Y	-46.33%
Dividend Ex-Date	-	Quick Ratio	1.50	Sales Y/Y TTM	11.17%	Profit Margin	-27.66%	RSI (14)	59.61	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	1.55	EPS Q/Q	-17.92%	SMA20	9.68%	Beta	0.73	Target Price	24.79
Payout	-	Debt/Eq	2.34	Sales Q/Q	7.81%	SMA50	4.57%	Rel Volume	0.68	Prev Close	13.66
Employees	1488	LT Debt/Eq	0.70	Earnings	Oct 30 BMO	SMA200	-11.96%	Avg Volume	1.72M	Price	13.32
IPO	Oct 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.37% 5.20%	Trades		Volume	1,163,950	Change	-2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14.50
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$30
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform	$18 → $30
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy	$24 → $30
Nov-20-23	Resumed	JP Morgan	Neutral	$15
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral	$85 → $25
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight	$45
Aug-04-23	Initiated	SVB Securities	Outperform	$51
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line	$33
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral	$53 → $46
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $104
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$99 → $50
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$89 → $107
Jan-05-23	Reiterated	H.C. Wainwright	Buy	$100 → $140
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$74 → $89
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral	$90 → $70
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy	$115
Feb-08-22	Initiated	Loop Capital	Buy	$200
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform	$98

Show Previous Ratings

Dec-09-25 05:31AM	Medtronic changes investor relations leadership ahead of diabetes spinout (MedTech Dive) +5.31%
Dec-01-25 07:00AM	Novocure Appoints Company President Frank Leonard as Chief Executive Officer (Business Wire) -8.82%
Nov-26-25 07:00AM	Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-12-25 10:00AM	2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon (Motley Fool)
07:00AM	Novocure to Participate in 2025 Jefferies Global Healthcare Conference (Business Wire)
04:22PM	Loading…
Oct-30-25 04:22PM	NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
10:30AM	Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:20AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 07:00AM	Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress (Business Wire) +7.67%
Oct-01-25 07:00AM	Novocure to Report Third Quarter 2025 Financial Results (Business Wire) +8.20%
Sep-29-25 04:30PM	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting (Business Wire)
Sep-16-25 05:28AM	Novocure obtains approval for Optune Lua device in Japan to treat NSCLC (Medical Device Network)
Sep-15-25 07:00AM	Novocure's Optune Lua Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
04:26AM	Loading…
Aug-29-25 04:26AM	2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts (Motley Fool)
Aug-28-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
Aug-25-25 07:00AM	Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain (Business Wire) -5.87%
Aug-22-25 01:37PM	NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer (Zacks)
Aug-20-25 07:00AM	Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer (Business Wire)
Aug-13-25 12:08PM	Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR) (Insider Monkey)
Jul-25-25 07:02AM	NovoCure: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 01:30PM	NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) -24.05%
08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Novocure Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-01-25 07:00AM	Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025 (Business Wire)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
07:00AM	Novocure to Report Second Quarter 2025 Financial Results (Business Wire)
Jun-18-25 12:00PM	What Makes NovoCure (NVCR) a New Buy Stock (Zacks)
Jun-06-25 12:26PM	NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial (Zacks)
02:05PM	Loading…
Jun-02-25 02:05PM	NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial (Benzinga) -10.83%
May-31-25 03:08PM	Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
08:00AM	Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting (Business Wire)
May-28-25 06:57AM	1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street (Motley Fool)
May-27-25 07:00AM	Novocure Announces Upcoming Investor Events (Business Wire)
May-16-25 10:00AM	The Next Frontier to Treat Cancer: Electricity (The Wall Street Journal)
May-15-25 09:55AM	Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? (Zacks)
Apr-29-25 09:55AM	Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High? (Zacks)
Apr-25-25 01:21PM	Why NovoCure Stock Skyrocketed This Week (Motley Fool)
Apr-24-25 07:03PM	Why NovoCure Stock Leaped 4% Higher Today (Motley Fool)
10:34AM	NovoCure Limited (NVCR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	NovoCure: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 10:16AM	Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting (Business Wire) +7.63%
06:45AM	Novocures device for metastatic NSCLC treatment gains CE Mark (Medical Device Network)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks) +5.97%
07:09AM	Novocure's Optune Lua Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Apr-17-25 10:01AM	NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-16-25 03:43PM	Why NovoCure Stock Was Withering on Wednesday (Motley Fool)
Apr-10-25 08:40AM	Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength? (Zacks) -5.13%
Apr-01-25 07:00AM	Novocure to Report First Quarter 2025 Financial Results (Business Wire)
Mar-21-25 05:16PM	Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth (SeekingAlpha)
Mar-04-25 07:00AM	Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference (Business Wire)
Feb-28-25 02:09AM	NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... (GuruFocus.com)
Feb-27-25 03:30PM	NovoCure (NVCR) Q4 2024 Earnings Call Transcript (Motley Fool) -12.43%
10:00AM	NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:20AM	NovoCure: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update (Business Wire)
Feb-20-25 10:00AM	NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 03:14PM	Jim Cramer on NovoCure Limited (NVCR): I Have Watched Them For Years And Years And Theyre Not Making Money (Insider Monkey)
Jan-22-25 04:00AM	Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland (Business Wire)
Jan-13-25 07:00AM	Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update (Business Wire)
Jan-03-25 07:00AM	Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-14-24 06:50AM	Novocure price target raised to $42 from $28 at Piper Sandler (TipRanks)
Dec-06-24 08:32AM	Why NovoCure Stock Was Winning Big This Week (Motley Fool) +5.11%
Dec-05-24 04:29AM	Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? (Motley Fool) -9.00%
Dec-03-24 02:51PM	Novocure Stock Earns 96 RS Rating (Investor's Business Daily)
07:17AM	Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint (TipRanks)
Dec-02-24 04:23PM	Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds (Investor's Business Daily) +48.95%
01:20PM	Novocure seeks approval after pancreatic cancer wearable scores at Phase III (Clinical Trials Arena)
10:12AM	NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients (Benzinga)
09:54AM	Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success (GuruFocus.com)
07:02AM	Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
07:00AM	Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer (Business Wire)
06:08AM	Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date (BioPharma Dive)
Nov-27-24 07:00AM	Novocure to Participate in Upcoming Investor Conferences (Business Wire) +10.12%
Nov-21-24 11:58AM	Novocure secures FDA approval for add-ons to brain cancer treatment wearable (Medical Device Network)
07:05AM	Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma (Business Wire)
07:00AM	FDA Approves Novocures Innovative HFE Transducer Arrays for Use With Optune Gio for Glioblastoma (Business Wire)
Oct-31-24 07:30AM	NovoCures Strong Q3 and Leadership Changes in 2024 (TipRanks) -10.65%
03:04AM	NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... (GuruFocus.com)
Oct-30-24 11:00PM	NovoCure (NVCR) Q3 2024 Earnings Call Transcript (Motley Fool)
08:15AM	NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	NovoCure: Q3 Earnings Snapshot (Associated Press Finance)
07:02AM	Novocure Appoints Christoph Brackmann as Chief Financial Officer (Business Wire)
07:00AM	Novocure Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-17-24 10:52AM	Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment (GuruFocus.com) -5.43%
08:00AM	NovoCure scoops FDA approval on wearable for metastatic cancer treatment (Clinical Trials Arena)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
08:16AM	Novocure wins FDA approval for electric field device in lung cancer (BioPharma Dive)
07:28AM	FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients (Benzinga)
06:26AM	Novocure shares soar 33% as FDA approves lung cancer treatment (Investing.com)
03:45AM	NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily) +10.71%
04:43PM	FDA Approves Novocure's Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer (Business Wire)
Oct-01-24 07:00AM	Novocure to Report Third Quarter 2024 Financial Results (Business Wire)
Sep-09-24 07:00AM	Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy (Business Wire)

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cordova Ashley	Chief Executive Officer	Sep 05 '25	Buy	12.22	81,550	996,859	437,569	Sep 08 07:10 AM
Brackmann Christoph	Chief Financial Officer	Jul 29 '25	Buy	11.59	20,000	231,800	141,150	Jul 30 04:33 PM
Stafford Kristin	Director	Jun 03 '25	Sale	17.28	999	17,259	3,054	Jun 04 04:26 PM
LEUNG GABRIEL	Director	Jun 03 '25	Sale	17.31	999	17,297	81,229	Jun 04 04:24 PM
Madden Martin J.	Director	Jun 03 '25	Sale	17.19	999	17,176	18,674	Jun 04 04:23 PM
Scannell Timothy J	Director	Jun 03 '25	Sale	17.32	999	17,299	6,018	Jun 04 04:22 PM
HILLEMAN JERYL L	Director	Jun 03 '25	Sale	17.26	999	17,247	5,591	Jun 04 04:17 PM
Ocean Allyson J	Director	Jun 03 '25	Sale	17.29	999	17,269	3,054	Jun 04 04:16 PM
VERNON W ANTHONY	Director	Jun 03 '25	Sale	17.35	999	17,329	167,887	Jun 04 04:14 PM
Hung David	Director	Jun 03 '25	Sale	17.30	999	17,280	12,195	Jun 04 04:11 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Jun 02 '25	Sale	17.50	30,196	528,413	168,452	Jun 04 04:09 PM
FRANCIS LEONARD	Officer	Jun 02 '25	Proposed Sale	19.11	30,196	577,046		Jun 02 04:25 PM
Paravasthu Mukund	Chief Operating Officer	May 03 '25	Sale	17.91	592	10,604	83,556	May 05 04:17 PM
MUKUND PARAVASTHU	Officer	May 05 '25	Proposed Sale	17.91	592	10,604		May 05 04:05 PM
Weinberg Uri	Chief Innovation Officer	Mar 03 '25	Sale	18.92	268	5,071	166,243	Mar 04 04:19 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Mar 03 '25	Sale	18.54	2,527	46,841	143,673	Mar 04 04:19 PM
Cordova Ashley	Chief Executive Officer	Mar 03 '25	Sale	18.54	2,053	38,055	204,005	Mar 04 04:19 PM
Paravasthu Mukund	Chief Operating Officer	Mar 03 '25	Sale	18.54	250	4,634	29,173	Mar 04 04:16 PM
FRANCIS LEONARD	Officer	Mar 03 '25	Proposed Sale	18.54	2,527	46,841		Mar 03 05:34 PM
MUKUND PARAVASTHU	Officer	Mar 03 '25	Proposed Sale	18.54	250	4,634		Mar 03 05:31 PM
URI WEINBERG	Officer	Mar 03 '25	Proposed Sale	18.92	268	5,071		Mar 03 05:20 PM
ASHLEY CORDOVA	Officer	Mar 03 '25	Proposed Sale	18.54	2,053	38,055		Mar 03 05:18 PM
WILHELMUS GROENHUYSEN	Officer	Mar 03 '25	Proposed Sale	18.54	3,165	58,667		Mar 03 05:13 PM
Weinberg Uri	Chief Innovation Officer	Feb 28 '25	Sale	18.75	4,637	86,949	166,511	Mar 03 04:28 PM
Leupin Nicolas	Chief Medical Officer	Feb 27 '25	Sale	20.02	991	19,844	50,133	Mar 03 04:28 PM
Puri Michal Nath	Chief Human Resources Officer	Feb 27 '25	Sale	20.02	1,387	27,773	108,706	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 27 '25	Sale	20.02	12,266	245,609	148,970	Mar 03 04:27 PM
Leonard Frank X	EVP, Pres., Novocure Oncology	Feb 28 '25	Sale	18.28	2,770	50,648	146,200	Mar 03 04:27 PM
Cordova Ashley	Chief Executive Officer	Feb 27 '25	Sale	20.02	11,153	223,323	208,399	Mar 03 04:26 PM
Cordova Ashley	Chief Executive Officer	Feb 28 '25	Sale	18.28	2,341	42,804	206,058	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 27 '25	Sale	20.02	1,646	32,959	29,791	Mar 03 04:26 PM
Paravasthu Mukund	Chief Operating Officer	Feb 28 '25	Sale	18.28	368	6,729	29,423	Mar 03 04:26 PM
URI WEINBERG	Officer	Feb 28 '25	Proposed Sale	18.75	4,637	86,949		Feb 28 05:01 PM
MUKUND PARAVASTHU	Officer	Feb 28 '25	Proposed Sale	18.28	368	6,729		Feb 28 04:50 PM
ASHLEY CORDOVA	Officer	Feb 28 '25	Proposed Sale	18.28	2,341	42,803		Feb 28 04:43 PM
WILHELMUS GROENHUYSEN	Officer	Feb 28 '25	Proposed Sale	18.28	3,202	58,546		Feb 28 04:40 PM
FRANCIS LEONARD	Officer	Feb 28 '25	Proposed Sale	18.28	2,770	50,647		Feb 28 04:38 PM
MUKUND PARAVASTHU	Officer	Feb 27 '25	Proposed Sale	20.02	1,646	32,959		Feb 27 04:42 PM
ASHLEY CORODVA	Officer	Feb 27 '25	Proposed Sale	20.02	11,153	223,322		Feb 27 04:39 PM
WILHELMUS GROENHUYSEN	Officer	Feb 27 '25	Proposed Sale	20.02	7,211	144,389		Feb 27 04:36 PM
FRANCIS LEONARD	Officer	Feb 27 '25	Proposed Sale	20.02	12,266	245,608		Feb 27 04:28 PM
Paravasthu Mukund	Chief Operating Officer	Jan 11 '25	Sale	26.81	2,160	57,906	31,437	Jan 15 04:23 PM
MUKUND PARAVASTHU	Officer	Jan 13 '25	Proposed Sale	26.75	2,160	57,788		Jan 13 05:28 PM
WILHELMUS C. GROENHUYSEN	Officer	Jan 02 '25	Proposed Sale	29.80	266,085	7,929,333		Jan 02 04:25 PM

NUVB

Nuvation Bio Inc

NVCR

NovoCure Ltd

Upgrade your FINVIZ experience